Invasive Pneumococcal Disease Surveillance, 1 July to 30 September 2018

Authors

  • Kate Pennington Communicable Disease Epidemiology and Surveillance Section, Office of Health Protection, Australian Government Department of Health, GPO Box 9484, MDP 14, Canberra, ACT 2601
  • Enhanced IPD Surveillance Working Group

DOI:

https://doi.org/10.33321/cdi.2019.43.57

Keywords:

invasive pneumococcal disease, Australia, epidemiology, IPD

Abstract

The number of notified cases of invasive pneumococcal disease (IPD) in the third quarter of 2018 was greater than the previous quarter, but lower than the third quarter of 2017. Following the July 2011 replacement of the 7-valent pneumococcal conjugate vaccine (7vPCV) in the childhood immunisation program with the 13-valent pneumococcal conjugate vaccine (13vPCV), there was an initial relatively rapid decline in disease due to the additional six serotypes covered by the 13vPCV across all age groups; however, more recently this decline is no longer evident. Over this period the number of cases due to the eleven serotypes additionally covered by the 23-valent pneumococcal polysaccharide vaccine (23vPPV), and also those serotypes not covered by any available vaccine, has been increasing steadily across all age groups.

Downloads

Download data is not yet available.

Downloads

Published

18/11/19

How to Cite

Pennington, Kate, and Enhanced IPD Surveillance Working Group. 2019. “Invasive Pneumococcal Disease Surveillance, 1 July to 30 September 2018”. Communicable Diseases Intelligence 43 (November). https://doi.org/10.33321/cdi.2019.43.57.

Issue

Section

Quarterly report

Categories